Last reviewed 2026-04-22 · How we verify

Comparator: VAQTA™

VAQTA is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.

VAQTA is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A virus infection in adults and children ≥12 months of age.

At a glance

Mechanism of action

VAQTA contains inactivated (killed) hepatitis A virus antigen, which triggers both humoral and cellular immune responses without causing disease. The vaccine induces production of anti-HAV antibodies that provide protective immunity against hepatitis A infection. Protection is typically achieved after the primary series and is long-lasting, with booster doses recommended for sustained immunity.

Approved indications

• Prevention of hepatitis A virus infection in adults and children ≥12 months of age

Common side effects

• Injection site soreness or pain
• Headache
• Fatigue
• Loss of appetite
• Fever

Key clinical trials

• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PHASE3)
• Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination (PHASE4)
• Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) (PHASE4)
• Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) (PHASE4)
• A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.